SCHEMBL2940146

SCHEMBL2940146

CCc1cc2ccccn2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
ALDH1A1 P00352 4/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
POLB P06746 2/20 0.43
KDM4E B2RXH2 2/20 0.43
ALOX15 P16050 1/20 0.43
TP53 P04637 3/20 0.39
METTL3 Q86U44 1/20 0.39
METTL14 Q9HCE5 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CYP1A2 P05177 2/20 0.36
CYP2A6 P11509 1/20 0.36
SSTR4 P31391 1/20 0.36
MAPK1 P28482 2/20 0.34
HPGD P15428 2/20 0.34
HRH3 Q9Y5N1 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2945627 0.85 NPC1 (0.41) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2944562 0.82 NPC1 (0.39) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2691734 0.80 NPC1 (0.43) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2760780 0.80 NPC1 (0.43) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL28195327 0.79 METTL3 (0.42) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL19682140 0.79 ALDH1A1 (0.40) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL24358125 0.79 NPC1 (0.40) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7171527 0.78 SIGMAR1 (0.39) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL27278125 0.78 MAPT (0.54) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL25509948 0.78 SLC6A4 (0.39) MAPTALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154519-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-17 WO disclosed
WO-2023081306-A1 INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT TACTOGEN INC (US) 2023-05-11 WO disclosed
CN-108676076-A The method for preparing guanosine cyclic mono-phosphate agonist 辛纳吉制药公司 2018-10-19 CN disclosed
CN-107090016-A The method for preparing guanosine cyclic mono-phosphate activator 辛纳吉制药公司 2017-08-25 CN disclosed
CN-105963676-A Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases 药物协和股份有限公司 2016-09-28 CN disclosed
CN-102858361-A Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases SYNERGY PHARMACEUTICALS INC 2013-01-02 CN disclosed
CN-101312973-B Indolizine derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2011-12-28 CN disclosed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 US disclosed
US-7799799-B2 Indolizine derivatives, method for preparing same, and therapeutic compositions comprising same SANOFI-AVENTIS (FR) 2010-09-21 US disclosed
EP-1957490-B1 NOVEL INDOLIZINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC COMPOSITIONS COMPRISING SAME SANOFI AVENTIS (FR) 2010-01-06 EP disclosed
CN-101312973-A Indolizine derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI AVENTIS (FR) 2008-11-26 CN disclosed
US-20080287485-A1 NOVEL INDOLIZINE DERIVATIVES, METHOD FOR PREPARING SAME, AND THERAPEUTIC COMPOSITIONS COMPRISING SAME SANOFI-AVENTIS (FR) 2008-11-20 US disclosed
US-20080176896-A1 Modulators of cellular adhesion BAUSCH + LOMB IRELAND LIMITED (IE) 2008-07-24 US disclosed
US-7314938-B2 Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. SUNESIS PHARMACEUTICALS, INC. (US) 2008-01-01 US disclosed
CN-1582168-A Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions SCHERING CORP (US) 2005-02-16 CN disclosed
US-4400387-A USEFUL IN VETERINARY MEDICINE FOR TREATMENT OF PSYCHOLOGICAL DISORDERS S. A. LABAZ-SANOFI N.V. (FR) 1983-08-23 US disclosed
US-4103012-A CARDIOVASCULAR DISORDERS LABAZ (FR) 1978-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF BTK, SYK, LCK MAPT 4467/4885ALDH1A1 3488/4885NPC1 3233/4885
US-20080287485-A1 NOVEL INDOLIZINE DERIVATIVES, METHOD FOR PREPARING SAME, AND THERAPEUTIC COMPOSITIONS COMPRISING SAME INMT, IDO1, IDO2 MAPT 1061/4885ALDH1A1 1233/4885NPC1 1172/4885
US-20080176896-A1 Modulators of cellular adhesion ITGB1, VCAM1, ITGB8 MAPT 3828/4885ALDH1A1 112/4885NPC1 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.